HIF-1α siRNA and cisplatin in combination suppresstumor growth in a nude mice model of esophageal squamous cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 473-477

  Liao, Hong Ying ^a   Wang, Gui Ping ^b   Gu, Li Jia ^a   Huang, Shao hong ^a   Chen, Xiu Ling ^a   Li, Yun ^a   Cai, Song Wang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Esophageal squamous cell carcinoma; HIF 1 ; RNA interference

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84866444565     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.473     Document Type: Article

References (23)

1. Angaji SA, Hedayati SS, Poor RH, et al (2010). Application of RNA interference in treating human diseases. J Genet, 89, 527-37.
2. Bazarbashi S, Abdelsalam M, Amin T, et al (2008). Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus. Chemotherapy, 54, 315-22.
3. Chen C, Yu Z (2009). siRNA targeting HIF-1alpha induces apoptosis of pancreatic cancer cells through NF-kappaB-independent and -dependent pathways under hypoxic conditions. Anticancer Res, 29, 1367-72.
4. Chen Y, Lu Y, Lu C, et al (2009). Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. Pathol Oncol Res, 15, 487-93.
5. Cho SH, Shim HJ, Lee SR, et al (2008). Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus, 21, 697-703.
6. Duyndam MC, van Berkel MP, Dorsman JC, et al (2007).Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulateHypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol, 74, 191-201.
7. Flamant L, Notte A, Ninane N, et al (2010). Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer, 9, 191.
8. Hammond EM, Giaccia AJ (2005). The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun, 331, 718-25.
9. Khan MN, Bhattacharyya T, Andrikopoulos P, et al (2011). Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1alpha-mediated apoptosis. Br J Cancer, 104, 1151-9.
10. Kim TH, Hur EG, Kang SJ, et al (2011). NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1{alpha}. Cancer Res, 71, 2260-75.
11. Kimura S, Kitadai Y, Tanaka S, et al (2004). Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer, 40, 1904-12.
12. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al (2001). Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res, 61, 1830-2.
13. Kurokawa T, Miyamoto M, Kato K, et al (2003). Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer, 89, 1042-7.
14. Matsuyama T, Nakanishi K, Hayashi T, et al (2005). Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci, 96, 176-82.
15. Rapisarda A, Shoemaker RH, Melillo G (2004). Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle, 3, 172-5.
16. Seeber LM, Zweemer RP, Verheijen RH, et al (2010). Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int, 2010, 580971.
17. Sithanandam G, Fornwald LW, Fields J, et al (2005). Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene, 24, 1847-59.
18. Takashima N, Ishiguro H, Kuwabara Y, et al (2008). Gene expression profiling of the response of esophageal carcinoma cells to cisplatin. Dis Esophagus, 21, 230-5.
19. Tzao C, Lee SC, Tung HJ, et al (2008). Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers, 25,141-8.
20. Wang G, Ye Y, Yang X, et al (2011). Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One, 6, e14573.
21. Welsh S, Williams R, Kirkpatrick L, et al (2004). Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther, 3, 233-44.
22. Wu XA, Sun Y, Fan QX, et al (2007). Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia. Zhonghua Yi Xue Za Zhi, 87, 2640-4.
23. Yonesaka K, Tamura K, Kurata T, et al (2006). Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer, 118, 812-20.